BridgeBio Pharma (BBIO) Accounts Payables (2018 - 2026)

BridgeBio Pharma's Accounts Payables history runs 9 years deep, the most recent figure standing at $29.1 million for Q1 2026.

• In Q1 2026, Accounts Payables rose 5.57% year-over-year to $29.1 million; the TTM figure through Mar 2026 stood at $29.1 million (up 5.57% YoY), while the FY2025 annual figure was $36.2 million, up 276.67% from the prior year.
• Accounts Payables came in at $29.1 million for Q1 2026 at BridgeBio Pharma, down from $36.2 million in the prior quarter.
• In the past five years, Accounts Payables ranged from a high of $36.2 million in Q4 2025 to a low of $3.9 million in Q2 2023.
• A 5-year average of $14.5 million and a median of $10.7 million in 2023 frame the typical range for Accounts Payables.
• Across the five-year window, Accounts Payables slumped 60.62% in 2022 and surged 482.17% in 2025, its largest moves.
• BridgeBio Pharma's Accounts Payables stood at $11.6 million in 2022, then retreated by 7.81% to $10.7 million in 2023, then slipped by 9.73% to $9.6 million in 2024, then jumped by 276.67% to $36.2 million in 2025, then fell by 19.79% to $29.1 million in 2026.
• According to Business Quant data, Accounts Payables over the past three periods registered $29.1 million, $36.2 million, and $18.7 million for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison